Mannheim, Germany–(ENEWSPF)–May 11, 2012. The administration of the non-psychotropic plant constituent cannabidiol (CBD) is associated with a significant reduction in psychotic symptoms in patients with schizophrenia, according to clinical trial data published in the journal Translational Psychiatry.
An international team of researchers from Germany and the United States performed a four week, double-blind, randomized clinical trial assessing the clinical relevance of cannabidiol versus amisulpride, a potent antipsychotic agent, in patients with acute schizophrenia.
Researchers reported…
